Imfinzi

(Durvalumab)

Phase 3Monoclonal antibody

Durvalumab is used to treat certain types of lung cancer and bladder cancer by helping the immune system recognize and attack cancer cells.[1] Imfinzi is currently being investigated across 128 indications[3], with its most advanced program in Phase 3.[1]

Imfinzi is one of 1679 small molecule programs targeting Glioma. It is currently in Phase 3.

128

Indications

653

Total Trials

Active Trials

1,678

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Pancreatic CarcinomaActive, not recruiting

Polycythemia VeraActive, not recruiting

Head and Neck CarcinomaActive, not recruiting

Small Cell CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

PlasmacytomaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

GliomaPhase 2

Active, not recruiting

Pancreatic CarcinomaPhase 3

Active, not recruiting

Polycythemia VeraPhase 1

Active, not recruiting

Head and Neck CarcinomaPhase 1/Phase 2

Active, not recruiting

Small Cell CarcinomaPhase 2

Active, not recruiting

Pancreatic NeoplasmPhase 1

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

PlasmacytomaPhase 1

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Showing 10 of 128 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

28 2

Halaven

Eisai

Preclinical

38 3

Tykerb

GSK

Preclinical

80 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

MS Contin

Merck & Co.

Preclinical

2 6

Voltaren

Novartis

Preclinical

1 7

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 8

Acupan

YYonsei University

Preclinical

1 9

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Gallbladder Cancer

NCT03257761

Q4 2026

Phase 2Recruiting

Hepatocellular Carcinoma

NCT03482102

Phase 2Active, not recruiting

Germ Cell Tumor

NCT03158064

Phase 2Active, not recruiting

Melanoma

NCT05061134

Phase 2Active, not recruiting

Non-Squamous NSCLC

NCT04163432

Phase 2Recruiting

Hepatocellular Carcinoma

NCT04988945

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer19 trials

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Terminated·EEmory University·Phase 1·NCT04348292·3 enrolled

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Terminated·MMayo Clinic·Phase 1·NCT05443971·4 enrolled

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Not yet recruiting·—·Phase 2·NCT07288034·535 enrolled

Show 16 more trials

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05221840·1,051 enrolled

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer

Terminated·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT03030131·50 enrolled

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04385368·89 enrolled

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT05848843

RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

Completed· AstraZeneca logo

AstraZeneca··NCT05933044·662 enrolled

Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Unknown status·HHui Bu·Phase 4·NCT04356222·30 enrolled

Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04255836·35 enrolled

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03693300·117 enrolled

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Recruiting·GGeorgetown University·Phase 2·NCT04499053·18 enrolled

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT04513925·829 enrolled

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT02452463·8 enrolled

A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05941897·39 enrolled

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Withdrawn·EETOP IBCSG Partners Foundation·Phase 2·NCT05718297

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT04889066

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04642469·30 enrolled

Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy

Unknown status·IInstituto Portugues de Oncologia, Francisco Gentil, Porto·Phase 1/2·NCT05267392·30 enrolled

Hepatocellular Carcinoma12 trials

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07081633·114 enrolled

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT06526104·32 enrolled

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT02519348·433 enrolled

Show 9 more trials

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Recruiting·EEnrico De Toni·Phase 2·NCT05844046·83 enrolled

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

Unknown status·ZZhejiang University·Phase 2·NCT05312216·25 enrolled

Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

Recruiting·UUNICANCER·Phase 2/3·NCT06904170·196 enrolled

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Completed·SSun Yat-sen University·Phase 2·NCT04945720·30 enrolled

Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

Not yet recruiting·CCenter Eugene Marquis·Phase 2·NCT07122089·80 enrolled

Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma

Recruiting·ZZhiyong Huang·Phase 1·NCT06470256·50 enrolled

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Recruiting·TThe University of Hong Kong·Phase 2·NCT04988945·33 enrolled

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Active, not recruiting·DDavendra Sohal·Phase 2·NCT05027425·30 enrolled

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Recruiting·MMassachusetts General Hospital·Phase 2·NCT03482102·70 enrolled

Breast Cancer10 trials

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 1/2·NCT03594396·54 enrolled

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Recruiting·IIFOM ETS - The AIRC Institute of Molecular Oncology·Phase 2·NCT05582538·37 enrolled

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT01042379·5,000 enrolled

Show 7 more trials

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Completed·YYonsei University·Phase 2·NCT03608865·30 enrolled

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Completed·CCanadian Cancer Trials Group·Phase 1·NCT02649686·15 enrolled

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

Completed·UUNICANCER·Phase 2·NCT02997995·61 enrolled

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT04176848·15 enrolled

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03874325·17 enrolled

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Completed·CCentro Nacional de Investigaciones Oncologicas CARLOS III·Phase 1·NCT02802098·25 enrolled

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT03544125·3 enrolled

Lung Cancer10 trials

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02937818·72 enrolled

Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04762030·39 enrolled

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

Active, not recruiting·UUniversity of Nebraska·Phase 1/2·NCT04748419·6 enrolled

Show 7 more trials

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT02542293·953 enrolled

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT03275597·17 enrolled

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Withdrawn·PPeregrine Pharmaceuticals·Phase 2·NCT02673814

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Completed·SSWOG Cancer Research Network·Phase 2/3·NCT02766335·116 enrolled

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03164616·1,186 enrolled

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03944772·247 enrolled

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Active, not recruiting·TTrans Tasman Radiation Oncology Group·Phase 2·NCT05796089·35 enrolled

Biliary Tract Cancer9 trials

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Not yet recruiting·YYonsei University·Phase 1/2·NCT07269158·160 enrolled

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Active, not recruiting·AAkeso·Phase 3·NCT06591520·682 enrolled

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

Active, not recruiting·—·Phase 2·NCT04308174·45 enrolled

Show 6 more trials

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT03046862·31 enrolled

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07107750·48 enrolled

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Recruiting·DDai, Guanghai·Phase 2·NCT06708858·35 enrolled

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04238637·50 enrolled

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Recruiting·SSeoul National University Hospital·Phase 2·NCT04298008·26 enrolled

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Active, not recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT04781192·40 enrolled

86 more indications

Tremelimumab7 trials

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Recruiting·UUniversity of California, San Diego·Phase 1·NCT06710223·20 enrolled

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Completed·—·Phase 1/2·NCT03751761·58 enrolled

Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC

Completed·CCentre Georges Francois Leclerc·Phase 1/2·NCT03202758·57 enrolled

Show 4 more trials

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06045975·30 enrolled

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Completed·SSeoul National University Hospital·Phase 2·NCT06446570·18 enrolled

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Completed·CCatherine Shu·Phase 1·NCT03085849·2 enrolled

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02643303·58 enrolled

Small Cell Lung Cancer7 trials

REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Completed· AstraZeneca logo

AstraZeneca··NCT06826677·71 enrolled

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04951115·6 enrolled

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer

Terminated·SSe-Hoon Lee·Phase 2·NCT04525391·4 enrolled

Show 4 more trials

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03043872·987 enrolled

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Unknown status·UUniversity of Sydney·Phase 2·NCT03994393·100 enrolled

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

Active, not recruiting·MMichael Hopp·Phase 2·NCT04602533·105 enrolled

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

Unknown status·SSamsung Medical Center·Phase 2·NCT03585998·51 enrolled

Durvalumab6 trials

1st Line Durvalumab in PS 2 NSCLC Patients

Active, not recruiting·SSwiss Cancer Institute·Phase 2·NCT03620669·48 enrolled

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Withdrawn·IIndiana University·Phase 2·NCT05757843

Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)

Active, not recruiting·AAssociation NVALT Studies·Phase 3·NCT04597671·170 enrolled

Show 3 more trials

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Recruiting·CCentre Leon Berard·Phase 2·NCT06393816·80 enrolled

PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

Completed·RRadboud University Medical Center·Phase 1/2·NCT03829007·33 enrolled

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Unknown status·SShanghai Chest Hospital·N/A·NCT04985851·90 enrolled

Bladder Cancer6 trials

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04960709·712 enrolled

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

Completed·FFundacion CRIS de Investigación para Vencer el Cáncer·Phase 2·NCT03472274·101 enrolled

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated·SStanford University·Phase 2·NCT03912818·7 enrolled

Show 3 more trials

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03459846·154 enrolled

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Recruiting·UUniversity College, London·Phase 1/2·NCT04106115·64 enrolled

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03258593·15 enrolled

Chemotherapy6 trials

Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study

Unknown status·EElizabeth Dudnik·Phase 2·NCT05262985·22 enrolled

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04449861·166 enrolled

Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT04765709·10 enrolled

Show 3 more trials

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Unknown status·YYou Lu·Phase 2·NCT05092412·30 enrolled

Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT03704480·106 enrolled

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT03611556·213 enrolled

Advanced Solid Tumors4 trials

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04261075·57 enrolled

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02718911·72 enrolled

Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT03851614·90 enrolled

Show 1 more trial

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02705482·58 enrolled

Ovarian Cancer4 trials

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02431559·53 enrolled

Trial in Patients With Relapsed Ovarian Cancer

Completed·NNordic Society of Gynaecological Oncology - Clinical Trials Unit·Phase 2·NCT03267589·25 enrolled

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Unknown status·YYonsei University·Phase 2·NCT03699449·104 enrolled

Show 1 more trial

NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study

Not yet recruiting·BBritish Columbia Cancer Agency·Phase 2·NCT06650709·40 enrolled

Non-squamous NSCLC3 trials

Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

Active, not recruiting·UUniversity of Utah·Phase 2·NCT04163432·43 enrolled

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03057106·301 enrolled

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04686305·244 enrolled

Soft Tissue Sarcoma3 trials

A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma

Unknown status·YYonsei University·Phase 1/2·NCT03802071·44 enrolled

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Completed·YYonsei University·Phase 2·NCT03798106·46 enrolled

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03317457·103 enrolled

Prostate Cancer3 trials

Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03385655·200 enrolled

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04089553·59 enrolled

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Terminated·UUniversity of Washington·Phase 2·NCT04336943·6 enrolled

Intrahepatic Cholangiocarcinoma3 trials

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting·MMayo Clinic·Phase 1·NCT06058663·16 enrolled

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05672537·70 enrolled

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Recruiting·WWest China Hospital·Phase 2·NCT06859684·25 enrolled

Esophageal Cancer2 trials

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab

Active, not recruiting·—·Phase 2·NCT03653052·18 enrolled

Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW

Not yet recruiting·UUniversity Medical Center Groningen·Phase 1·NCT07196384·15 enrolled

Trial2 trials

......SMARTEST Trial......

Completed·UUniversity Health Network, Toronto·Phase 2·NCT05380713·30 enrolled

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Adenocarcinoma2 trials

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

Terminated·BBaptist Health South Florida·Phase 2·NCT03490760·9 enrolled

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04105270·82 enrolled

Endometrial Cancer2 trials

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03015129·80 enrolled

A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06746116·45 enrolled

Squamous Cell Carcinoma2 trials

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

Completed·UUniversity of Colorado, Denver·Phase 1·NCT03635164·21 enrolled

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 1/2·NCT03784066·21 enrolled

Resectable NSCLC2 trials

Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

Terminated·—·Phase 1·NCT03818776·7 enrolled

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05211895·860 enrolled

Locally Advanced2 trials

Tumor Treating Fields for Locally Advanced NSCLC

Recruiting·UUniversity of Utah·Phase 1·NCT06124118·30 enrolled

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT04416633·100 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Completed·SSeoul National University Hospital·Phase 2·NCT03292250·180 enrolled

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Unknown status·CChinese Academy of Medical Sciences·N/A·NCT04851132·33 enrolled

Solid Tumors2 trials

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Completed·—·Phase 2·NCT03911557·14 enrolled

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT04613492·40 enrolled

Mesothelioma2 trials

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Recruiting·—·Phase 1/2·NCT05932199·52 enrolled

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Completed·PPrECOG, LLC.·Phase 2·NCT02899195·55 enrolled

Elderly Patients2 trials

Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC

Terminated·RRush University Medical Center·Phase 2·NCT04441138·10 enrolled

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03975114·460 enrolled

Lymphoma2 trials

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

Unknown status·SSingapore General Hospital·Phase 2·NCT03054532·22 enrolled

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Recruiting·UUniversity of Virginia·Phase 1/2·NCT03161223·148 enrolled

Safety and Efficacy2 trials

Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC

Completed·SSeoul National University Hospital·Phase 1/2·NCT04124991·24 enrolled

Durvalumab Long-Term Safety and Efficacy Study

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT04078152·163 enrolled

Adjuvant Treatment1 trial

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Withdrawn·CCatherine Shu·Phase 2·NCT04625699

Head and Neck1 trial

Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.

Completed·HHellenic Cooperative Oncology Group·Phase 2·NCT02882308·41 enrolled

Oropharyngeal Cancer1 trial

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Active, not recruiting·UUniversity of Birmingham·Phase 3·NCT04116047·785 enrolled

Malignant Pleural Mesothelioma1 trial

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Terminated·—·Phase 2·NCT03075527·19 enrolled

Stem Cell Transplant1 trial

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Terminated·LLudwig Institute for Cancer Research·Phase 1·NCT02716805·6 enrolled

Recruiting·MMayo Clinic·Phase 2·NCT05388006·27 enrolled

Advanced or Metastatic Solid Tumour1 trial

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT04999969·126 enrolled

Treatment1 trial

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

Radiotherapy1 trial

A Trial of Radiotherapy and Durvalumab in DLBCL and FL

Completed·AAustin Health·Phase 1·NCT03610061·34 enrolled

Patients With Advanced Solid Tumors1 trial

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03907475·115 enrolled

Gallbladder Cancer1 trial

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT03257761·55 enrolled

Adjuvant1 trial

Renal Adjuvant MultiPle Arm Randomised Trial

Recruiting·UUniversity College, London·Phase 3·NCT03288532·1,750 enrolled

Intratumoral Injection1 trial

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Terminated· Moderna logo

Moderna·Phase 1/2·NCT03323398·79 enrolled

Advanced Solid Tumours1 trial

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Completed·UUNICANCER·Phase 1/2·NCT03518606·126 enrolled

Doxorubicin1 trial

Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

Completed·SSeoul National University Hospital·Phase 2·NCT04224337·16 enrolled

Carboplatin1 trial

FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

Completed·CCentre Leon Berard·Phase 2·NCT03723967·104 enrolled

Adjuvant Therapy1 trial

Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC

Active, not recruiting·—·Phase 2·NCT06490107·40 enrolled

Pancreatic Cancer1 trial

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

Completed·BBaki Topal·Phase 2·NCT04156087·12 enrolled

Cancer of the Esophagus1 trial

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

Unknown status·UUniversity of Cologne·Phase 2·NCT04159974·56 enrolled

Neuroendocrine Carcinoma1 trial

First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06070740·22 enrolled

Transitional Cell Carcinoma1 trial

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03430895·15 enrolled

Sarcoma1 trial

Pulmonary sarcomatoid_MEDI4736+Treme

Completed·SSeoul National University Hospital·Phase 2·NCT03022500·32 enrolled

Proton Therapy1 trial

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Unknown status·SSamsung Medical Center·Phase 2·NCT03450967·31 enrolled

Unresectable1 trial

Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment

Not yet recruiting·—·Phase 2·NCT07168668·90 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Unknown status·—·Phase 2·NCT04221555·68 enrolled

Gastric Cancer1 trial

Vactosertib and Durvalumab in Gastric Cancer

Unknown status·HHark Kyun Kim·Phase 2·NCT04893252·55 enrolled

Colorectal Cancer1 trial

Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

Unknown status·OOspedale Policlinico San Martino·Phase 2·NCT05382741·182 enrolled

Liver Cancer1 trial

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Active, not recruiting·—·Phase 1·NCT04605731·25 enrolled

Oropharynx Cancer1 trial

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Terminated·WWake Forest University Health Sciences·Phase 1·NCT02827838·17 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

Microbiota1 trial

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

Not yet recruiting·FFundación GECP·Phase 2·NCT07247786·68 enrolled

Locally Advanced or Metastatic NSCLC1 trial

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05374603·47 enrolled

Toxicity1 trial

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03847649·60 enrolled

Metastatic Colorectal Cancer1 trial

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

Completed·—·Phase 1·NCT03005002·9 enrolled

Metastatic NSCLC1 trial

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Completed·UUNICANCER·Phase 2·NCT02117167·999 enrolled

Nasopharyngeal Carcinoma1 trial

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·TThe University of Hong Kong·Phase 2·NCT04447612·118 enrolled

Maintenance Treatment1 trial

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03319316

HER21 trial

TRUDI: TDXD+Durva in HER2+/Low IBC

Recruiting·FFilipa Lynce, MD·Phase 2·NCT05795101·63 enrolled

Phase 11 trial

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02027961·68 enrolled

Chemoradiotherapy1 trial

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Terminated·TThe Netherlands Cancer Institute·Phase 1·NCT04287894·18 enrolled

Multiple Myeloma1 trial

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02807454·37 enrolled

Triple-Negative Breast Cancer1 trial

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Recruiting·QQueen Mary University of London·Phase 2·NCT06954480·140 enrolled

Pleural Mesothelioma1 trial

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Completed·PPrECOG, LLC.·Phase 3·NCT04334759·214 enrolled

Papilloma1 trial

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Terminated·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT03618134·19 enrolled

Thyroid Cancer1 trial

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03122496·13 enrolled

Metastatic1 trial

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04387084·10 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Unknown status·IInstitut Català d'Oncologia·Phase 1·NCT03799744·20 enrolled

Cholangiocarcinoma1 trial

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT06440993·42 enrolled

Chemoradiation1 trial

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Unknown status·FFondazione IRCCS Policlinico San Matteo di Pavia··NCT04364776·100 enrolled

Refractory Solid Tumors1 trial

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02403271·124 enrolled

Advanced Cancers1 trial

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04902040·19 enrolled

Infusion1 trial

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Recruiting·IIsala·Phase 4·NCT06031233·679 enrolled

Germ Cell Tumor1 trial

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03158064·30 enrolled

Consolidation Immunotherapy1 trial

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.

Unknown status·UUniversity Hospital, Essen·Phase 2·NCT04202809·90 enrolled

Renal Cell Cancer1 trial

WIRE - Novel Treatments in Renal Cell Cancer

Unknown status·CCCTU- Cancer Theme·Phase 2·NCT03741426·60 enrolled

Immune Response1 trial

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Recruiting·FFundación GECP··NCT06634199·50 enrolled

Cancer1 trial

Combining Epigenetic And Immune Therapy to Beat Cancer.

Completed·IInstitut Bergonié·Phase 2·NCT04705818·164 enrolled

Urothelial Carcinoma1 trial

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02901548·17 enrolled

Patients With Solid Tumors1 trial

Durvalumab in HIV-1 Patients With Solid Tumors

Completed·SSpanish Lung Cancer Group·Phase 2·NCT03094286·20 enrolled

Melanoma1 trial

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT05061134·194 enrolled

Regulatory

FDA Approval Timeline[4]

May 1, 2017

Imfinzi

BLA 761069

May 1, 2017

IMFINZI

BLA BLA761069

Sources

References

[1]
ClinicalTrials.gov — 653 trial records for Durvalumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Durvalumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Durvalumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA 761069). U.S. Food & Drug Administration.
[5]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death 1 Ligand 1 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Imfinzi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer19 trials

Hepatocellular Carcinoma12 trials

Breast Cancer10 trials

Lung Cancer10 trials

Biliary Tract Cancer9 trials

Tremelimumab7 trials

Small Cell Lung Cancer7 trials

Durvalumab6 trials

Bladder Cancer6 trials

Chemotherapy6 trials

Advanced Solid Tumors4 trials

Ovarian Cancer4 trials

Non-squamous NSCLC3 trials

Soft Tissue Sarcoma3 trials

Prostate Cancer3 trials

Intrahepatic Cholangiocarcinoma3 trials

Esophageal Cancer2 trials

Trial2 trials

Adenocarcinoma2 trials

Endometrial Cancer2 trials

Squamous Cell Carcinoma2 trials

Resectable NSCLC2 trials

Locally Advanced2 trials

Esophageal Squamous Cell Carcinoma2 trials

Solid Tumors2 trials

Mesothelioma2 trials

Elderly Patients2 trials

Lymphoma2 trials

Safety and Efficacy2 trials

Adjuvant Treatment1 trial

Head and Neck1 trial

Oropharyngeal Cancer1 trial

Malignant Pleural Mesothelioma1 trial

Stem Cell Transplant1 trial

Immunotherapy1 trial

Immune1 trial

Chronic Lymphocytic Leukemia1 trial

Advanced or Metastatic Solid Tumour1 trial

Treatment1 trial

Radiotherapy1 trial

Patients With Advanced Solid Tumors1 trial

Gallbladder Cancer1 trial

Adjuvant1 trial

Intratumoral Injection1 trial

Advanced Solid Tumours1 trial

Doxorubicin1 trial

Carboplatin1 trial

Adjuvant Therapy1 trial

Pancreatic Cancer1 trial

Cancer of the Esophagus1 trial

Neuroendocrine Carcinoma1 trial

Transitional Cell Carcinoma1 trial

Sarcoma1 trial

Proton Therapy1 trial

Unresectable1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Gastric Cancer1 trial

Colorectal Cancer1 trial

Liver Cancer1 trial

Oropharynx Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

Microbiota1 trial

Locally Advanced or Metastatic NSCLC1 trial

Toxicity1 trial

Metastatic Colorectal Cancer1 trial

Metastatic NSCLC1 trial

Nasopharyngeal Carcinoma1 trial

Maintenance Treatment1 trial

HER21 trial

Phase 11 trial

Chemoradiotherapy1 trial

Multiple Myeloma1 trial

Triple-Negative Breast Cancer1 trial